BeiGene
BGNE
#934
Rank
S$28.26 B
Marketcap
$254.06
Share price
-2.10%
Change (1 day)
-4.25%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : S$4.51 Billion

According to BeiGene 's latest financial reports the company has S$4.51 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$S$4.67 B-20.5%
2022-12-31$S$5.87 B-29.12%
2021-12-31$S$8.29 B61.97%
2020-12-31$S$5.11 B288.08%
2019-12-31$S$1.31 B-44.94%
2018-12-31$S$2.39 B161.78%
2017-12-31$S$0.91 B79.18%
2016-12-31$S$0.51 B385.86%
2015-12-31$S$0.10 B208.76%
2014-12-31$S$34.04 M-169.39%
2013-12-31$-S$49.07 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
S$8.07 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.87 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA